First-Wave-Logo-FINAL-RGB[1].jpg
First Wave BioPharma to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
05 sept. 2023 07h00 HE | First Wave BioPharma, Inc.
BOCA RATON, Fla., Sept. 05, 2023 (GLOBE NEWSWIRE) --  First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First-Wave-Logo-FINAL-RGB[1].jpg
First Wave BioPharma to Attend the 36th National Cystic Fibrosis Education Conference (July 28-30)
15 juin 2023 11h31 HE | First Wave BioPharma, Inc.
BOCA RATON, Fla., June 15, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
First-Wave-Logo-FINAL-RGB[1].jpg
First Wave BioPharma CEO James Sapirstein to Present at 2023 BIO International Conference
15 mai 2023 07h00 HE | First Wave BioPharma, Inc.
BOCA RATON, Fla., May 15, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ: FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
First-Wave-Logo-FINAL-RGB[1].jpg
First Wave BioPharma Completes Patient Screening For Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis
11 mai 2023 07h00 HE | First Wave BioPharma, Inc.
Top line data read-out on track for July 2023 BOCA RATON, Fla., May 11, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. ("First Wave BioPharma" or the “Company”) (NASDAQ: FWBI), a...
First-Wave-Logo-FINAL-RGB[1].jpg
First Wave BioPharma to Participate in EF Hutton Inaugural Global Conference
02 mai 2023 07h30 HE | First Wave BioPharma, Inc.
BOCA RATON, Fla., May 02, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ: FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
First-Wave-Logo-FINAL-RGB[1].jpg
First Wave Biopharma Exceeds 50% Enrollment Target for Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis
25 avr. 2023 07h00 HE | First Wave BioPharma, Inc.
Three U.S. clinical trial sites actively screening and enrolling patientsTop line data of adrulipase in Cystic Fibrosis patients expected in July 2023 BOCA RATON, Fla., April 25, 2023 (GLOBE...
First-Wave-Logo-FINAL-RGB[1].jpg
First Wave BioPharma Announces Phase 2 Adrulipase Combination Trial Data to be Presented at the 2023 Digestive Disease Week (DDW) Conference
21 févr. 2023 07h00 HE | First Wave BioPharma, Inc.
BOCA RATON, Fla., Feb. 21, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
First-Wave-Logo-FINAL-RGB[1].jpg
First Wave BioPharma Chairman and CEO Issues Letter to Stockholders
13 févr. 2023 07h00 HE | First Wave BioPharma, Inc.
BOCA RATON, Fla., Feb. 13, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First-Wave-Logo-FINAL-RGB[1].jpg
First Wave BioPharma Announces Expansion of Adrulipase Intellectual Property Portfolio
25 janv. 2023 07h00 HE | First Wave BioPharma, Inc.
BOCA RATON, Fla., Jan. 25, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ: FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First-Wave-Logo-FINAL-RGB[1].jpg
First Wave BioPharma Provides Update on IND Filing For Phase 2 Trial of Enhanced Microgranule Formulation of Adrulipase for Exocrine Pancreatic Insufficiency
13 janv. 2023 16h00 HE | First Wave BioPharma, Inc.
BOCA RATON, Fla., Jan. 13, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...